Anthropometric Measurements and Lipid Profiles to Detect Early Lipodystrophy in Antiretroviral Therapy Experienced HIV-Infected Children in the Chapas-3 Trial

Abstract

Background

Few studies have investigated objective markers of lipodystrophy in African children. We compared body circumferences, skin-fold thickness (SFT) and lipids in antiretroviral therapy (ART)-naive and stavudine (d4T)-exposed children with HIV-uninfected controls.

Methods

In the CHAPAS-3 trial, HIV-infected children (ART-naive or on d4T for ≥2 years without clinical lipodystrophy) were randomized to d4T, abacavir or zidovudine with lamivudine (3TC) plus a non-nucleoside reverse transcriptase inhibitor. Mid-upper-arm circumference (MUAC) and calf circumference (CC), SFT (biceps, triceps, sub-scapular and supra-iliac) and fasting lipids (total cholesterol [TC], low-density lipoprotein [LDL], high-density lipoprotein [HDL] and triglycerides [TRIG]) were measured at randomization in all HIV-infected children, and in HIV-uninfected controls. Age- and sex-adjusted z-scores of MUAC, CC, SFT and the sum of SFT (SSF) using Dutch reference data were compared across groups using linear regression.

Results

Of 496 children, 49% were male, 299 (median age 2.5 years [IQR 1.5–4.0]) were ART-naive, 109 (median age 6 years [IQR 5.5–7.0]) were ART-experienced and 88 (median age 2.2 years [IQR 1.5–3.0]) were control children. Overall, 100% and 95% of ART-experienced children had been on d4T plus 3TC and nevirapine, respectively, for a median 3.5 years (IQR 2.6–4.2). Mean (sd) weight-for-age z-scores and MUAC z-scores were -1.51 (1.29) versus -0.90 (0.88) versus -0.33 (1.15) and -1.56 (1.25) versus -1.24 (0.97) versus -0.65 (1.06) in ART-naive versus -experienced versus controls, respectively (all P<0.02). The mean (sd) of SSF was lower in the ART-experienced (-0.78 [1.28]) than in the ART-naive (-0.32 [1.09]; P<0.0001) children and controls (-0.29 [0.88]; P<0.002). ART-experienced children had higher mean fasting TC, LDL and HDL but lower TRIG compared to ART-naive children (P-values <0.0001), and higher TC and HDL but lower TRIG compared to controls (P-values <0.01).

Conclusions

In ART-experienced children on d4T-containing regimens, we observed lower SFT and higher TC and LDL values compared to ART-naive children and HIV-uninfected controls.

References

Boulle

, Orrel

, Kaplan

Substitutions due to antiretroviral toxicity or contraindication in the first 3 years of antiretroviral therapy in a large South African cohort. Antivir Ther 2007; 12: 753–760.

Grinspoon

, Carr

Cardiovascular risk and body-fat abnormalities in HIV-infected adults. N Engl J Med 2005; 352: 48–62.

Alves

, Oliveira

A.C.

, Brites

Lipodystrophic syndrome in children and adolescents infected with the human immunodeficiency virus. Braz J Infect Dis 2008; 12: 342–348.

Innes

, Levin

, Cotton

Lipodystrophy syndrome in HIV-infected children on HAART. South Afr J HIV Med 2009; 10: 76–80.

, Hegele

R.A.

HIV-associated dyslipidaemia: pathogenesis and treatment. Lancet Infect Dis 2007; 7: 787–796.

Aurpibul

, Puthanakit

, Lee

, Mangklabruks

, Sirisanthana

Lipodystrophy and metabolic changes in HIV-infected children on non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy. Antivir Ther 2007; 12: 1247–1254.

Ene

, Goetghebuer

, Hainaut

, Peltier

, Toppet

, Levy

Prevalence of lipodystrophy in HIV-infected children: a cross-sectional study. Eur J Pediatr 2007; 166: 13–21.

Jevtović

, Salemovic

, Ranin

, Brmbolic

, Djurkovic-Djakovic

The prognosis of pediatric AIDS in serbia. Curr HIV Res 2009; 7: 287–292.

Kinabo

G.D.

, Sprengers

, Msuya

L.J.

Prevalence of lipodystrophy in HIV-infected children in Tanzania on HAART. Pediatr Infect Dis J 2013; 32: 39–44.

10.

Parakh

, Dubey

A.P.

, Kumar

, Maheshwari

Lipodystrophy and metabolic complications of highly active antiretroviral therapy. Indian J Pediatr 2009; 76: 1017–1021.

11.

Piloya

, Bakeera-Kitaka

, Kekitiinwa

, Kamya

M.R.

Lipodystrophy among HIV-infected children and adolescents on highly active antiretroviral therapy in Uganda: a cross sectional study. J Int AIDS Soc 2012; 15: 17427.

12.

Sawawiboon

, Wittawatmongkol

, Phongsamart

, Prasitsuebsai

, Lapphra

, Chokephaibulkit

Lipodystrophy and reversal of facial lipoatrophy in perinatally HIV-infected children and adolescents after discontinuation of stavudine. Int J STD AIDS 2012; 23: 497–501.

13.

Werner

M.L.

, Pone

M.V.

, Fonseca

V.M.

, Chaves

C.R.

Lipodystrophy syndrome and cardiovascular risk factors in children and adolescents infected with HIV/AIDS receiving highly active antiretroviral therapy. J Pediatr (Rio J) 2010; 86: 27–32.

14.

Alam

, Cortina-Borja

, Goetghebuer

, Marczynska

, Vigano

, Thorne

Body fat abnormality in HIV-infected children and adolescents living in Europe: prevalence and risk factors. J Acquir Immune Defic Syndr 2012; 59: 314–324.

15.

Morén

, Noguera-Julian

, Rovira

Mitochondrial impact of human immunodeficiency virus and antiretrovirals on infected pediatric patients with or without lipodystrophy. Pediatr Infect Dis J 2011; 30: 992–995.

16.

Arpadi

S.M.

, Bethel

, Horlick

Longitudinal changes in regional fat content in HIV-infected children and adolescents. AIDS 2009; 23: 1501–1509.

17.

Carter

R.J.

, Wiener

, Abrams

E.J.

Dyslipidemia among perinatally HIV-infected children enrolled in the PACTS-HOPE cohort, 1999–2004: a longitudinal analysis. J Acquir Immune Defic Syndr 2006; 41: 453–460.

18.

Hartman

, Verweel

, de Groot

, Hartwig

N.G.

Detection of lipoatrophy in human immunodeficiency virus-1-infected children treated with highly active antiretroviral therapy. Pediatr Infect Dis J 2006; 25: 427–431.

19.

Krause

J.C.

, Toye

M.P.

, Fisher

D.J.

, Stechenberg

B.W.

, Reiter

E.O.

, Allen

H.F.

Metabolic abnormalities in human immunodeficiency virus-infected children: two-year follow-up. J Pediatr Endocrinol Metab 2009; 22: 345–351.

20.

Popielska

[Lipodystrophy in HIV infected children]. Pol Merkuriusz Lek 2008; 24: 408–413. Polish.

21.

Ramalho

L.C.

, Goncalves

E.M.

, de Carvalho

W.R.

Abnormalities in body composition and nutritional status in HIV-infected children and adolescents on antiretroviral therapy. Int J STD AIDS 2011; 22: 453–456.

22.

Spoulou

, Kanaka-Gantenbein

, Bathrellou

Monitoring of lipodystrophic and metabolic abnormalities in HIV-1 infected children on antiretroviral therapy. Hormones (Athens) 2011; 10: 149–155.

23.

Beregszaszi

, Dollfus

, Levine

Longitudinal evaluation and risk factors of lipodystrophy and associated metabolic changes in HIV-infected children. J Acquir Immune Defic Syndr 2005; 40: 161–168.

24.

Resino

, Micheloud

, Larru

Immunological recovery and metabolic disorders in severe immunodeficiency HIV type 1-infected children on highly active antiretroviral therapy. AIDS Res Hum Retroviruses 2008; 24: 1477–1484.

25.

World Health Organization. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection. Recommendations for a public health approach. Geneva: World Health Organization 2013.

26.

Ministry Of Health Zambia. Guidelines for antiretroviral therapy for HIV in infants and children in Zambia. Lusaka: Ministry of Health, Zambia 2010.

27.

Ministry Of Health Uganda. The integrated national guidelines on antiretroviral therapy, prevention of mother to child transmission of HIV and infant and young child feeding. Kampala: Ministry of Health, Uganda 2011.

28.

Kline

M.W.

, Dunkle

L.M.

, Church

J.A.

A Phase I/II evaluation of stavudine (d4T) in children with human immunodeficiency virus infection. Pediatrics 1995; 96: 247–252.

29.

Aurpibul

, Puthanakit

, Taejaroenkul

, Sirisanthana

Recovery from lipodystrophy in HIV-infected children after substitution of stavudine with zidovudine in a non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy. Pediatr Infect Dis J 2012; 31: 384–388.

30.

Desai

, Mullen

, Mathur

Lipodystrophy in pediatric HIV. Indian J Pediatr 2008; 75: 351–354.

31.

World Health Organization. Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach - 2010 revision. Geneva: World Health Organization 2010.

32.

Gerver

W.J.M.

, de Bruin

Paediatric morphometrics: a reference manual. Utrecht: Wetenschappelijke uitgeverij Bunge 1996.

33.

Kanjanavanit

, Puthanakit

, Vibol

High prevalence of lipid abnormalities among antiretroviral-naive HIV-infected Asian children with mild-to-moderate immunosuppression. Antivir Ther 2011; 16: 1351–1355.

34.

Chauhan

, Paunikar

Update on pediatric hyperlipidemia. Curr Opin Pediatr 2014; 26: 252–258.

35.

Souza

S.J.

, Luzia

L.A.

, Santos

S.S.

, Rondo

P.H.

Lipid profile of HIV-infected patients in relation to antiretroviral therapy: a review. Rev Assoc Med Bras 2013; 59: 186–198.

36.

Nikolic

, Katsiki

, Montalto

, Isenovic

E.R.

, Mikhailidis

D.P.

, Rizzo

Lipoprotein subfractions in metabolic syndrome and obesity: clinical significance and therapeutic approaches. Nutrients 2013; 5: 928–948.

37.

Gallego-Escuredo

J.M.

, Del Mar Gutierrez

, Diaz-Delfin

Differential effects of efavirenz and lopinavir/ritonavir on human adipocyte differentiation, gene expression and release of adipokines and pro-inflammatory cytokines. Curr HIV Res 2010; 8: 545–553.

38.

Musiime

, Kaudha

, Kayiwa

Antiretroviral drug resistance profiles and response to second-line therapy among HIV-1 infected Ugandan children. AIDS Res Hum Retroviruses 2013; 29: 449–455.

39.

L'homme

R.F.

, Kabamba

, Ewings

F.M.

Nevirapine, stavudine and lamivudine pharmacokinetics in African children on paediatric fixed-dose combination tablets. AIDS 2008; 22: 557–565.

40.

McComsey

G.A.

, Lo Re

III , O'Riordan

Effect of reducing the dose of stavudine on body composition, bone density, and markers of mitochondrial toxicity in HIV-infected subjects: a randomized, controlled study. Clin Infect Dis 2008; 46: 1290–1296.

41.

Aurpibul

, Puthanakit

, Sirisanthana

Haematological changes after switching from stavudine to zidovudine in HIV-infected children receiving highly active antiretroviral therapy. HIV Med 2008; 9: 317–321.

42.

Pryce

, Pierre

R.B.

, Steel-Duncan

Safety of antiretroviral drug therapy in Jamaican children with HIV/AIDS. West Indian Med J 2008; 57: 238–245.

43.

Recent FDA approvals and changes. AIDS Patient Care STDS 2011; 25: 124–125.

44.

Grigsby

I.F.

, Pham

, Mansky

L.M.

, Gopalakrishnan

, Mansky

K.C.

Tenofovir-associated bone density loss. Ther Clin Risk Manag 2010; 6: 41–47.

45.

Purswani

, Patel

, Kopp

J.B.

Tenofovir treatment duration predicts proteinuria in a multi-ethnic United States cohort of children and adolescents with perinatal HIV-1 infection. Pediatr Infect Dis J 2013; 32: 495–500.